Van Wichelen Natan, Estévez-Danta Andrea, Belova Lidia, den Ouden Fatima, Verougstraete Nick, Roggeman Maarten, Boogaerts Tim, Quireyns Maarten, Robeyns Rani, De Brabanter Nik, Quintana José Benito, Rodil Rosario, van Nuijs Alexander L N, Covaci Adrian, Gys Celine
Toxicological Centre, University of Antwerp, Antwerp 2610, Belgium; Exposome Center of Excellence, University of Antwerp, Universiteitsplein 1, Antwerp 2610, Belgium.
Aquatic One Health Research Center (ARCUS) & Department of Analytical Chemistry, Nutrition and Food Chemistry, Universidade de Santiago de Compostela, R. Constantino Candeira S/N, IIAA building, Santiago de Compostela 15782, Spain.
J Pharm Biomed Anal. 2024 Sep 15;248:116335. doi: 10.1016/j.jpba.2024.116335. Epub 2024 Jul 3.
Synthetic cathinones are the second largest group of new psychoactive substances (NPS) monitored by the European Monitoring Centre for Drugs and Drug Addiction. Although 3-methylmethcathinone (3-MMC, CHNO) is legally banned in many countries, it is readily available for purchase online and on the street. Due to the scarcity of information regarding the pharmacokinetic and toxicological profile of 3-MMC, understanding its biotransformation pathways is crucial in determining its potential toxicity in humans and in the development of analytical methods for screening of human matrices. To gain more insight, Phase I and Phase II in vitro biotransformation of 3-MMC was investigated using human liver microsomes and human liver cytosol. Suspect and non-target screening approaches were employed to identify metabolites. To confirm in vitro results in an in vivo setting, human matrices (i.e., plasma, urine, saliva and hair) positive for 3-MMC (n=31) were screened. In total three biotransformation products were identified in vitro: CHNO (a hydroxylated derivate), CHNO (a keto-reduced derivate) and CHNO (an N-desmethyl derivate). All three were confirmed as human metabolites in respectively 16 %, 52 % and 42 % of the analysed human samples. In total, 61 % of the analysed samples were positive for at least one of the three metabolites. Interestingly, three urine samples were positive for all three metabolites. The presence of 3-MMC in saliva and hair indicates its potential applicability in specific settings, e.g., roadside testing or chronic consumption analysis. To our knowledge, CHNO was not detected before in vivo. Although some of these metabolites have been previously suggested in vitro or in a single post mortem case report, a wide in vivo confirmation including the screening of four different human matrices was performed for the first time. These metabolites could serve as potential human biomarkers to monitor human 3-MMC consumption effectively.
合成卡西酮是欧洲药物和药物成瘾监测中心监测的第二大类新型精神活性物质(NPS)。尽管3-甲基甲卡西酮(3-MMC,C₁₀H₁₃NO)在许多国家被法律禁止,但它在网上和街头仍很容易买到。由于关于3-MMC药代动力学和毒理学特征的信息匮乏,了解其生物转化途径对于确定其对人类的潜在毒性以及开发用于筛查人体基质的分析方法至关重要。为了深入了解,使用人肝微粒体和人肝细胞溶胶研究了3-MMC的I相和II相体外生物转化。采用可疑和非目标筛查方法来鉴定代谢物。为了在体内环境中确认体外结果,对3-MMC呈阳性的人体基质(即血浆、尿液、唾液和毛发,n = 31)进行了筛查。总共在体外鉴定出三种生物转化产物:C₁₀H₁₂NO(一种羟基化衍生物)、C₁₀H₁₃NO(一种酮还原衍生物)和C₉H₁₁NO(一种N-去甲基衍生物)。在分别16%、52%和42%的分析人体样本中,这三种产物均被确认为人体代谢物。总共,61%的分析样本对这三种代谢物中的至少一种呈阳性。有趣的是,有三个尿液样本对所有三种代谢物均呈阳性。唾液和毛发中3-MMC的存在表明其在特定环境中的潜在适用性,例如路边检测或长期消费分析。据我们所知,C₁₀H₁₂NO以前在体内未被检测到。尽管其中一些代谢物先前已在体外或单个死后病例报告中被提出,但首次进行了广泛的体内确认,包括对四种不同人体基质的筛查。这些代谢物可作为潜在的人体生物标志物,以有效监测人体对3-MMC的消费情况。